Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dexamethasone intravitreal implant Clear all
Completed No phase listed Observational

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

NCT02188173
View directory record Official record
Conditions
Macular Edema
Interventions
dexamethasone 700 ㎍ intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 2Phase 3 Interventional

Ozurdex for Macular Edema Post Membrane Peeling

NCT01273727
View directory record Official record
Conditions
Epiretinal Membrane, Cellophane Maculopathy, Macular Edema, Retinal Edema
Interventions
dexamethasone
Drug
Lead sponsor
Retina Specialists, PC
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Avastin
Drug
Lead sponsor
Long Island Vitreoretinal Consultants
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 28, 2026, 4:14 PM EDT
Not listed Phase 4 Interventional

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

NCT04529512
View directory record Official record
Conditions
Ocular Disease Requiring Surgery
Interventions
DEXTENZA®
Drug
Lead sponsor
Nathan Steinle
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Paso Robles, California • San Luis Obispo, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

NCT02471651
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 28, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168298
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

NCT01027650
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
AGN208397 intravitreal injection, dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Phase II Combination Steroid and Anti-VEGF for Persistent DME

NCT01945866
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 28, 2026, 4:14 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Corticosteroid for Diabetic Macular Edema (DME) Study

NCT07843849
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy
Interventions
Intravitreal dexamethasone implant
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 4:14 PM EDT
Terminated Not applicable Interventional

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

NCT01410201
View directory record Official record
Conditions
Epiretinal Membrane, Macular Edema
Interventions
Dexamethasone Intravitreal Implant
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chesterfield, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

NCT01309451
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bevacizumab, dexamethasone intravitreal implant
Drug
Lead sponsor
Maturi, Raj K., M.D., P.C.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

NCT00464685
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham injection, Laser Photocoagulation
Drug · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 28, 2026, 4:14 PM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

NCT03832179
View directory record Official record
Conditions
Diabetic Macular Edema, Cataract
Interventions
Bevacizumab, Ranibizumab, Aflibercept, Ozurdex
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 28, 2026, 4:14 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

NCT04082962
View directory record Official record
Conditions
Exudative Retinal Detachment and Uveal Melanoma
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Ivana K. Kim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 4:14 PM EDT
Not listed Phase 4 Interventional

Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME

NCT04038125
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Interventions
Ozurdex Drug Implant Product
Drug
Lead sponsor
Retina Macula Specialists of Miami, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
North Miami Beach, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 28, 2026, 4:14 PM EDT
Completed No phase listed Observational Results available

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

NCT03889444
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 28, 2026, 4:14 PM EDT
Completed No phase listed Observational Results available

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Sep 28, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

NCT02036424
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Raj K. Maturi, MD
Individual
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 28, 2026, 4:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

NCT06536491
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
Drug
Lead sponsor
Eclipse Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 4:14 PM EDT